GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
37.95
-0.28 (-0.75%)
Jul 25, 2025, 4:00 PM - Market closed
GSK Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
$593,563
Profits / Employee
$59,358
Market Cap
76.00B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
Dec 31, 2023 | 70,212 | 812 | 1.17% |
Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
Dec 31, 2017 | 98,462 | -838 | -0.84% |
Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
Dec 31, 2013 | 99,451 | -37 | -0.04% |
Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
Dec 31, 2011 | 97,389 | 928 | 0.96% |
Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
Dec 31, 2009 | 99,913 | 910 | 0.92% |
Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
Dec 31, 2007 | 103,483 | 788 | 0.77% |
Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
Dec 31, 2005 | 100,728 | 709 | 0.71% |
Dec 31, 2004 | 100,019 | -900 | -0.89% |
Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
Dec 31, 2001 | 107,470 | -47 | -0.04% |
Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
GSK News
- 1 day ago - GSK's blood cancer drug gets EU approval for multiple myeloma - Reuters
- 1 day ago - GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults - Business Wire
- 2 days ago - US FDA extends review of GSK's blood cancer drug - Reuters
- 7 days ago - GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt - WSJ
- 7 days ago - GSK shares fall after blood cancer drug likely headed for U.S. rejection - Reuters
- 7 days ago - FDA Committee Votes Against GSK Blood Cancer Drug Blenrep - WSJ
- 8 days ago - GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights - GlobeNewsWire
- 8 days ago - FDA advisers vote against combination therapies of GSK's blood cancer drug - Reuters